Literature DB >> 3312033

[Comparison of the effectiveness of ceftazidime and cefazolin/tobramycin in patients with inflammatory diseases of the lower respiratory tract].

N Vetter1, H Feist, C Armbruster, M Drlicek.   

Abstract

We compared the efficacy of ceftazidime and cefazolin in combination with tobramycin in the treatment of lower respiratory tract infections. Bacterial pathogens were isolated from sputum or bronchial secretions from 92 patients. The clinical results were identical in both groups: All patients showed an improvement of the clinical symptoms or were cured. 88% of the patients in the ceftazidime-group and 76% of the patients in the cefazolin/tobramycin-group showed an eradication of the pathogens without superinfection. This difference was not statistically significant (p = 0.095). Monotherapy with ceftazidime was clinically and bacteriologically as effective as a combination therapy with cefazolin and tobramycin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312033     DOI: 10.1007/BF01645869

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

1.  Criteria for the assessment of susceptibility to ceftazidime using the disc diffusion procedure.

Authors:  H Grimm
Journal:  Infection       Date:  1983       Impact factor: 3.553

2.  Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients.

Authors:  B E de Pauw; F Kauw; H Muytjens; K J Williams; T Bothof
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

3.  Can the third-generation cephalosporins eliminate the need for antimicrobial combinations?

Authors:  R C Moellering
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

4.  Treatment of community-acquired pneumonias.

Authors:  P P McKellar
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

5.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

  5 in total
  1 in total

Review 1.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.